SK282425B6 - Benzimidazolové zlúčeniny, farmaceutické zmesi obsahujúce tieto zlúčeniny a použitie týchto zlúčenín - Google Patents

Benzimidazolové zlúčeniny, farmaceutické zmesi obsahujúce tieto zlúčeniny a použitie týchto zlúčenín Download PDF

Info

Publication number
SK282425B6
SK282425B6 SK1399-97A SK139997A SK282425B6 SK 282425 B6 SK282425 B6 SK 282425B6 SK 139997 A SK139997 A SK 139997A SK 282425 B6 SK282425 B6 SK 282425B6
Authority
SK
Slovakia
Prior art keywords
phenyl
benzimidazole
mixture
furanyl
mmol
Prior art date
Application number
SK1399-97A
Other languages
English (en)
Slovak (sk)
Other versions
SK139997A3 (en
Inventor
Lene Teuber
Frank W�Tjen
Yoshimasa Fukuda
Osamu Ushiroda
Toshiro Sasaki
Original Assignee
Neurosearch A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch A/S filed Critical Neurosearch A/S
Publication of SK139997A3 publication Critical patent/SK139997A3/sk
Publication of SK282425B6 publication Critical patent/SK282425B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D521/00—Heterocyclic compounds containing unspecified hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SK1399-97A 1995-04-21 1996-04-17 Benzimidazolové zlúčeniny, farmaceutické zmesi obsahujúce tieto zlúčeniny a použitie týchto zlúčenín SK282425B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK46095 1995-04-21
PCT/EP1996/001606 WO1996033194A1 (en) 1995-04-21 1996-04-17 Benzimidazole compounds and their use as modulators of the gaba a receptor complex

Publications (2)

Publication Number Publication Date
SK139997A3 SK139997A3 (en) 1998-05-06
SK282425B6 true SK282425B6 (sk) 2002-01-07

Family

ID=8093808

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1399-97A SK282425B6 (sk) 1995-04-21 1996-04-17 Benzimidazolové zlúčeniny, farmaceutické zmesi obsahujúce tieto zlúčeniny a použitie týchto zlúčenín

Country Status (22)

Country Link
US (2) US5922724A (is)
EP (3) EP1164134A1 (is)
JP (2) JP3342874B2 (is)
KR (2) KR100297445B1 (is)
CN (2) CN1072669C (is)
AT (2) ATE210132T1 (is)
AU (2) AU695957B2 (is)
BR (1) BR9608048A (is)
CA (2) CA2218493C (is)
CZ (1) CZ287545B6 (is)
DE (2) DE69617665T2 (is)
EE (1) EE04310B1 (is)
HU (1) HUP9801692A3 (is)
IS (1) IS1959B (is)
NO (1) NO314504B1 (is)
NZ (1) NZ307521A (is)
PL (1) PL183853B1 (is)
RU (1) RU2135493C1 (is)
SK (1) SK282425B6 (is)
TR (1) TR199701218T2 (is)
UA (1) UA54393C2 (is)
WO (2) WO1996033194A1 (is)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU726447B2 (en) 1996-10-21 2000-11-09 Neurosearch A/S 1-phenyl-benzimidazole compounds and their use as BAGA-A receptor modulators
GB9622370D0 (en) 1996-10-28 1997-01-08 Merck Sharp & Dohme Therapeutic agents
GB9702524D0 (en) * 1997-02-07 1997-03-26 Merck Sharp & Dohme Therapeutic agents
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
AU764479B2 (en) * 1998-10-29 2003-08-21 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme
EP1132087A4 (en) 1998-11-13 2002-06-26 Fujisawa Pharmaceutical Co REMEDIES FOR POLYKYSTIC OVARY SYNDROME
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US6627624B1 (en) 1999-04-02 2003-09-30 Neurogen Corporation Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6358949B1 (en) 1999-04-02 2002-03-19 Neurogen Corporation Aryl and hetroaryl fused aminoalkyl-imidazole derivatives: selective modulators of bradykinin B2 receptors
ES2226812T3 (es) * 1999-04-02 2005-04-01 Neurogen Corporation Derivados de aminoalquilimidazol condensados con arilo y heteroarilo:moduladores selesctivos de los preseptores gabaa.
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6281237B1 (en) 1999-04-02 2001-08-28 Neurogen Corporation N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
DE60025604T2 (de) 1999-06-22 2006-07-27 Neurosearch A/S Benzimidazol-derivate und diese enthaltende pharmazeutische zusammensetzungen
DE60006541D1 (de) 1999-06-30 2003-12-18 Merck & Co Inc Src-kinase hemmende verbindungen
US6316444B1 (en) 1999-06-30 2001-11-13 Merck & Co., Inc. SRC kinase inhibitor compounds
WO2001000207A1 (en) * 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
SK2512002A3 (en) * 1999-08-19 2002-07-02 Nps Pharma Inc Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
PA8535601A1 (es) * 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
GB0208394D0 (en) * 2002-04-11 2002-05-22 Merck Sharp & Dohme Therapeutic agents
JP2006516626A (ja) * 2003-01-28 2006-07-06 スミスクライン ビーチャム コーポレーション 化学的化合物
US7335777B2 (en) 2003-04-03 2008-02-26 Neurosearch A/S Benzimidazole derivatives and their use for modulating the GABAA receptor complex
JP2006522070A (ja) 2003-04-03 2006-09-28 ニューロサーチ、アクティーゼルスカブ ベンズイミダゾール誘導体及びこれをｇａｂａａ受容体複合体をモジュレートするために使用する方法
US7700638B2 (en) * 2003-10-23 2010-04-20 N. V. Organon 1,5,7-trisubstituted benzimidazole derivatives and their use for modulating the GABAA receptor complex
CA2604516A1 (en) 2005-04-13 2006-10-19 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
US20070015782A1 (en) * 2005-04-15 2007-01-18 Eisai Co., Ltd. Benzimidazole compound
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US7923464B2 (en) 2005-12-05 2011-04-12 Neurosearch A/S Benzimidazole derivatives and their use for modulating the GABAA receptor complex
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
TWI391381B (zh) 2006-03-24 2013-04-01 Neurosearch As 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
MX373178B (es) * 2007-04-03 2020-04-22 Fmc Corp Star Fungicidas de benceno sustituido.
CA2694216A1 (en) 2007-07-24 2009-01-29 Astellas Pharma Inc. Benzimidazole derivative
KR20090024998A (ko) * 2007-09-05 2009-03-10 제일모직주식회사 분자 내에 정공수송기와 전자수송기를 동시에 가지는바이폴라 유기화합물을 포함하는 유기광전소자용 재료 및이를 이용한 유기광전소자
WO2010055126A1 (en) * 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
WO2010087319A1 (ja) 2009-01-27 2010-08-05 アステラス製薬株式会社 前立腺癌治療剤として有効な物質のスクリーニング方法
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
AU2010218714A1 (en) * 2009-02-26 2011-09-08 Eisai R&D Management Co., Ltd. Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
WO2011047315A1 (en) 2009-10-15 2011-04-21 Concert Pharmaceuticals, Inc. Subsitituted benzimidazoles
EP2903980B1 (en) * 2012-10-01 2017-07-19 F. Hoffmann-La Roche AG Benzimidazoles as cns active agents
WO2014096965A2 (en) 2012-12-21 2014-06-26 Rvx Therapeutics Inc. Novel heterocyclic compounds as bromodomain inhibitors
TWI606048B (zh) * 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物
SG11201510409QA (en) 2013-06-21 2016-01-28 Zenith Epigenetics Corp Novel bicyclic bromodomain inhibitors
WO2015004533A2 (en) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
WO2015015318A2 (en) 2013-07-31 2015-02-05 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
EP3227280B1 (en) 2014-12-01 2019-04-24 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
JP2017537946A (ja) 2014-12-11 2017-12-21 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての置換複素環
HK1245247A1 (zh) * 2014-12-17 2018-08-24 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
KR102446529B1 (ko) * 2017-01-10 2022-09-23 에테하 취리히 세포 보호 화합물 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2964942D1 (en) * 1978-04-17 1983-04-07 Basab Materialhantering Ab A device for raising and transport of goods
DE2853765A1 (de) * 1978-12-13 1980-06-26 Bayer Ag Verfahren zur herstellung von benzimidazolylbenzofuranen
US4329348A (en) * 1979-02-26 1982-05-11 Ciba-Geigy Corporation N-Oxacyclic-alkylpiperidines as psychostimulants
PH30434A (en) * 1989-04-07 1997-05-09 Janssen Pharmaceutica Nv Hydroxyalkylfuranyl derivatives
US5554630A (en) * 1993-03-24 1996-09-10 Neurosearch A/S Benzimidazole compounds
AU675484B2 (en) * 1993-03-24 1997-02-06 Neurosearch A/S Benzimidazole compounds, their use and preparation

Also Published As

Publication number Publication date
TR199701218T2 (xx) 1998-08-21
DE69636670T2 (de) 2007-02-08
CA2217601C (en) 2002-04-16
WO1996033194A1 (en) 1996-10-24
UA54393C2 (uk) 2003-03-17
DE69636670D1 (de) 2006-12-14
DE69617665T2 (de) 2002-05-08
NZ307521A (en) 1999-04-29
BR9608048A (pt) 1999-11-30
AU5689196A (en) 1996-11-07
NO974844D0 (no) 1997-10-20
ATE210132T1 (de) 2001-12-15
IS1959B (is) 2004-11-15
KR19990007942A (ko) 1999-01-25
US5922724A (en) 1999-07-13
EP0821684B1 (en) 2001-12-05
EP0821683B1 (en) 2006-11-02
EP0821684A1 (en) 1998-02-04
KR19990007941A (ko) 1999-01-25
PL183853B1 (pl) 2002-07-31
HUP9801692A3 (en) 2001-11-28
SK139997A3 (en) 1998-05-06
HUP9801692A2 (hu) 1999-03-29
RU2135493C1 (ru) 1999-08-27
EP0821683A1 (en) 1998-02-04
HK1015674A1 (en) 1999-10-22
NO974844L (no) 1997-12-16
US5902813A (en) 1999-05-11
IS4588A (is) 1997-10-13
JP3342874B2 (ja) 2002-11-11
JPH11501321A (ja) 1999-02-02
CA2218493C (en) 2005-02-22
ATE344257T1 (de) 2006-11-15
CZ287545B6 (en) 2000-12-13
CA2218493A1 (en) 1996-10-24
EE04310B1 (et) 2004-06-15
CN1072669C (zh) 2001-10-10
CA2217601A1 (en) 1996-10-24
KR100297445B1 (ko) 2001-10-25
AU5501496A (en) 1996-11-07
EE9700283A (et) 1998-06-15
CN1182426A (zh) 1998-05-20
CZ329297A3 (cs) 1998-03-18
CN1182427A (zh) 1998-05-20
DE69617665D1 (de) 2002-01-17
EP1164134A1 (en) 2001-12-19
WO1996033192A1 (en) 1996-10-24
NO314504B1 (no) 2003-03-31
JPH11501320A (ja) 1999-02-02
AU695957B2 (en) 1998-08-27
PL322892A1 (en) 1998-03-02
JP3040485B2 (ja) 2000-05-15

Similar Documents

Publication Publication Date Title
SK282425B6 (sk) Benzimidazolové zlúčeniny, farmaceutické zmesi obsahujúce tieto zlúčeniny a použitie týchto zlúčenín
DE69830403T2 (de) Inhibitoren des faktors xa mit einer neutralen gruppe mit p1-spezifität
CA2218552C (en) Benzimidazole compounds and their use as modulators of the gabaa receptor complex
CA2267114A1 (en) 1-phenyl-benzimidazole compounds and their use as gaba-a receptor modulators
MXPA05010449A (es) Derivados del bencimidazol y su uso para modular el complejo del receptor de gabaa.